肌缩侧面硬化症 (ALS) 遗传学和微生物群:全面审查
Mostafa Ahmed Kurdi1, Hidayah Alotaibi2, Asayel Tawfiq Alkhuraymi3
1Biology Department, College of Science, Taibah University, Medina 42353, Saudi Arabia.
International journal of molecular sciences
|February 27, 2026
概括
肌缩侧面硬化症 (ALS) 是一种复杂的神经退行性疾病. 新兴的基因和微生物组疗法提供了有前途的个性化治疗策略,可以减缓ALS的进展.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 微生物组研究 微生物组研究
背景情况:
- 肌缩侧面硬化 (ALS) 是一种进展性神经退行性疾病,影响运动神经元.
- 由于氧化应激和TDP-43蛋白质病变等重叠的分子途径,ALS与前性痴呆症 (FTD) 有共同特征.
- 遗传因素 (例如,C9orf72,SOD1) 和肠-大脑轴 (失调,代谢物) 都与ALS有关.
研究的目的:
- 审查当前对ALS作为多系统疾病的理解.
- 探索针对遗传因素和肠道微生物组的新疗法.
- 要突出转向个性化和多模式治疗策略的转变.
主要方法:
- 对ALS.中的遗传因素和分子过程的审查.
- 研究肠-大脑连接及其在ALS发病过程中的作用.
- 对新兴基因疗法 (ASOs,RNAi,CRISPR) 和微生物组调节治疗 (益生菌,FMT) 的分析.
主要成果:
- 确定关键的基因突变 (C9orf72,SOD1,TARDBP,FUS) 作为治疗点.
- 有证据表明,肠道失调和代谢物水平的变化会影响ALS的进展.
- 反感性寡核酸托弗森 (Tofersen) 是SOD1-ALS.基因疗法的最新进展.
结论:
- 病变是一种复杂的疾病,需要个性化治疗方法.
- 基因疗法和微生物干预显示出显著的治疗潜力,尽管在很大程度上是实验性的.
- 改进的诊断和早期的多模式策略对于管理ALS进展至关重要.
相关概念视频
Amyloid Fibrils
12.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.2K
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Lysosomal Hydrolases
4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K


